MedTrace Logo

A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

NCT07673029 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 228

Last updated 2026-06-29

No results posted yet for this study

Summary

This study is designed to compare efficacy and safety of GQ1005 versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer patients previously treated with trastuzumab and taxane.

Conditions

Interventions

DRUG

GQ1005

Administered I.V.

DRUG

T-DM1

Administered I.V.

Sponsors & Collaborators

  • GeneQuantum Healthcare (Suzhou) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Zefei Jiang, M.D. · The Fifth Medical Center of the Chinese People's Liberation Army General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-10
Primary Completion
2027-01-09
Completion
2028-01-09

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07673029 on ClinicalTrials.gov